Urologix, Inc.
ULGX · OTC
6/30/2014 | 6/30/2013 | 6/30/2012 | 6/30/2011 | |
|---|---|---|---|---|
| Revenue | $14,235 | $16,590 | $17,027 | $12,571 |
| % Growth | -14.2% | -2.6% | 35.4% | – |
| Cost of Goods Sold | $8,142 | $8,407 | $8,645 | $6,030 |
| Gross Profit | $6,093 | $8,183 | $8,382 | $6,541 |
| % Margin | 42.8% | 49.3% | 49.2% | 52% |
| R&D Expenses | $1,625 | $2,269 | $2,189 | $2,238 |
| G&A Expenses | $2,299 | $2,515 | $3,393 | $0 |
| SG&A Expenses | $8,149 | $10,234 | $10,420 | $8,005 |
| Sales & Mktg Exp. | $5,850 | $7,719 | $7,027 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,092 | $11,945 | $12,527 | $10,267 |
| Operating Income | -$6,930 | -$3,922 | -$4,145 | -$3,726 |
| % Margin | -48.7% | -23.6% | -24.3% | -29.6% |
| Other Income/Exp. Net | -$694 | -$356 | -$495 | $1 |
| Pre-Tax Income | -$7,624 | -$4,278 | -$4,640 | -$3,725 |
| Tax Expense | -$16 | $14 | $55 | $8 |
| Net Income | -$7,608 | -$4,292 | -$4,695 | -$3,733 |
| % Margin | -53.4% | -25.9% | -27.6% | -29.7% |
| EPS | -0.36 | -0.21 | -0.32 | -0.26 |
| % Growth | -71.4% | 34.4% | -23.1% | – |
| EPS Diluted | -0.36 | -0.21 | -0.32 | -0.26 |
| Weighted Avg Shares Out | 21,219 | 20,703 | 14,741 | 14,556 |
| Weighted Avg Shares Out Dil | 21,219 | 20,703 | 14,741 | 14,556 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $693 | $555 | $482 | $0 |
| Depreciation & Amortization | $587 | $674 | $695 | $565 |
| EBITDA | -$6,344 | -$3,048 | -$3,463 | -$3,160 |
| % Margin | -44.6% | -18.4% | -20.3% | -25.1% |